SLC12A2 and tuberous sclerosis: NKCC1 may be a promising target for thetreatment of specific epilepsies,141,142neurodevelopmental disorders including autism spectrum disorders and tuberous sclerosis,and neuropsychiatric disorders including schizophrenia, anxiety, pain, and braindegeneration or injury.143,144 The therapeutic relevance oftreatments based on NKCC1 channels is yet to be proven, also because the correlationbetween bioavailability in the brain and neuropsychiatric effects is unclear.